[{"address1": "3891 Ranchero Drive", "address2": "Suite 150", "city": "Ann Arbor", "state": "MI", "zip": "48108", "country": "United States", "phone": "734 887 3903", "website": "https://www.esperion.com", "industry": "Drug Manufacturers - Specialty & Generic", "industryKey": "drug-manufacturers-specialty-generic", "industryDisp": "Drug Manufacturers - Specialty & Generic", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.", "fullTimeEmployees": 240, "companyOfficers": [{"maxAge": 1, "name": "Mr. Sheldon L. Koenig", "age": 57, "title": "President, CEO & Director", "yearBorn": 1966, "fiscalYear": 2023, "totalPay": 1278804, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Eric J. Warren R.Ph.", "age": 51, "title": "Chief Commercial Officer", "yearBorn": 1972, "fiscalYear": 2023, "totalPay": 718859, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Benjamin  Halladay M.B.A.", "age": 37, "title": "Chief Financial Officer", "yearBorn": 1986, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Glenn P. Brame", "age": 65, "title": "Chief Technical Operations Officer", "yearBorn": 1958, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Benjamin O. Looker J.D.", "age": 41, "title": "General Counsel & Corporate Secretary", "yearBorn": 1982, "fiscalYear": 2023, "totalPay": 550350, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Tiffany  Aldrich M.B.A.", "title": "Associate Director of Corporate Communications", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Betty Jean Swartz", "title": "Chief Business Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 3, "boardRisk": 5, "compensationRisk": 6, "shareHolderRightsRisk": 9, "overallRisk": 6, "governanceEpochDate": 1730419200, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 2.12, "open": 2.2, "dayLow": 2.12, "dayHigh": 2.245, "regularMarketPreviousClose": 2.12, "regularMarketOpen": 2.2, "regularMarketDayLow": 2.12, "regularMarketDayHigh": 2.245, "beta": 0.996, "forwardPE": 17.0, "volume": 5869521, "regularMarketVolume": 5869521, "averageVolume": 3431231, "averageVolume10days": 3005170, "averageDailyVolume10Day": 3005170, "bid": 2.19, "ask": 2.22, "bidSize": 700, "askSize": 700, "marketCap": 433657248, "fiftyTwoWeekLow": 0.87, "fiftyTwoWeekHigh": 3.4, "priceToSalesTrailing12Months": 1.5611086, "fiftyDayAverage": 1.8856, "twoHundredDayAverage": 2.21195, "currency": "USD", "enterpriseValue": 513487584, "profitMargins": -0.35458001, "floatShares": 194821688, "sharesOutstanding": 196224992, "sharesShort": 35388048, "sharesShortPriorMonth": 38090309, "sharesShortPreviousMonthDate": 1726185600, "dateShortInterest": 1728950400, "sharesPercentSharesOut": 0.18030001, "heldPercentInsiders": 0.005, "heldPercentInstitutions": 0.69386, "shortRatio": 10.64, "shortPercentOfFloat": 0.1808, "impliedSharesOutstanding": 199168000, "bookValue": -1.769, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -98497000, "trailingEps": -0.88, "forwardEps": 0.13, "pegRatio": -0.56, "enterpriseToRevenue": 1.848, "enterpriseToEbitda": 102.903, "52WeekChange": 1.409091, "SandP52WeekChange": 0.3301804, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "ESPR", "underlyingSymbol": "ESPR", "shortName": "Esperion Therapeutics, Inc.", "longName": "Esperion Therapeutics, Inc.", "firstTradeDateEpochUtc": 1372253400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "00314c6d-38c1-3c8e-a318-bd51d9ba1c8c", "messageBoardId": "finmb_28236", "gmtOffSetMilliseconds": -18000000, "currentPrice": 2.21, "targetHighPrice": 16.0, "targetLowPrice": 2.5, "targetMeanPrice": 7.58, "targetMedianPrice": 6.5, "recommendationMean": 2.1, "recommendationKey": "buy", "numberOfAnalystOpinions": 6, "totalCash": 189304000, "totalCashPerShare": 0.965, "ebitda": 4990000, "totalDebt": 269135008, "quickRatio": 1.424, "currentRatio": 1.968, "totalRevenue": 277788000, "revenuePerShare": 1.907, "returnOnAssets": 0.01054, "freeCashflow": 6908125, "operatingCashflow": -9758000, "revenueGrowth": 1.863, "grossMargins": 0.6112, "ebitdaMargins": 0.01796, "operatingMargins": 0.034930002, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-11-07"}]